Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service thrombectomy, IVC filters & venous stents cases in Nebraska: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (194 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 300 | 18% |
| 2020 | 4 | 395 | 22% |
| 2021 | 3 | 337 | 27% |
| 2022 | 1 | 199 | 31% |
| 2023 | 1 | 274 | 35% |
| 2024 | 1 | 272 | 37% |
| 2025 from claims | – | 204 165–240 | 37% |
| 2026 forecast | – | 208 163–261 | 37% |
| 2027 forecast | – | 210 156–277 | 37% |
| 2028 forecast | – | 212 150–293 | 38% |
| 2029 forecast | – | 214 146–307 | 38% |
| 2030 forecast | – | 217 142–321 | 38% |
Mechanical thrombectomy, IVC filter placement, and iliac venous stenting. Professional codes (what the surgeon bills): CPT 37187, 37184, 37191, 37238.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Nebraska; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital. The share outside the hospital has moved −23 pts since 2019.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 28 | 2,235+1.2%/yr | +1.2%/yr | 1.6 | 18% | 3,030 in 2030+5.2%/yr |
| Michigan | 10 | 1,534−1.8%/yr | −1.8%/yr | 1.8 | 18% | 1,770 in 2030+2.4%/yr |
| Ohio | 6 | 1,351−4.1%/yr | −4.1%/yr | 1.2 | 0% | 1,470 in 2030+1.4%/yr |
| Indiana | 7 | 1,264+6.5%/yr | +6.5%/yr | 1.8 | 15% | 1,940 in 2030+7.4%/yr |
| Missouri | 8 | 855−5.5%/yr | −5.5%/yr | 1.4 | 0% | 790 in 2030−1.3%/yr |
| Wisconsin | 1 | 601−4.2%/yr | −4.2%/yr | 1.1 | 5% | 1,010 in 2030+9.1%/yr |
| Minnesota | 3 | 534−2.8%/yr | −2.8%/yr | 1.2 | 0% | 1,150 in 2030+14%/yr |
| Kansas | 2 | 454+4.3%/yr | +4.3%/yr | 1.1 | 0% | 920 in 2030+12%/yr |
| South Dakota | 6 | 318+3.2%/yr | +3.2%/yr | 2.5 | 0% | 220 in 2030−5.7%/yr |
| Iowa | 1 | 3090%/yr | 0%/yr | 0.7 | 0% | 490 in 2030+8.2%/yr |
| North Dakota | 1 | 126−1.2%/yr | −1.2%/yr | 1.3 | 0% | 260 in 2030+13%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral arterial intervention | 9 | 1,170−1.7%/yr | −1.7%/yr | 4.41.1× | 62% | 2,150 in 2030+11%/yr |
| Superficial venous ablation | 10 | 562−6.2%/yr | −6.2%/yr | 2.10.6× | 70% | 590 in 2030+0.9%/yr |
| Dialysis access | 7 | 526−11%/yr | −11%/yr | 2.10.4× | 3% | 610 in 2030+2.4%/yr |
| Carotid revascularization | 5 | 321−9.6%/yr | −9.6%/yr | 1.21.1× | 0% | 410 in 2030+4.2%/yr |
Thrombectomy, IVC filters & venous stents in every state, and its device makers · Every procedure market in Nebraska · Every state · Compare with Illinois
Stryker leads with 55% of company spending on these surgeons in 2025, +18 pts on 2024.
In 2025, 11 companies reported engagement with Nebraska’s surgeons worth $15K in consulting, speaking, meals and travel tied to these products, about $15K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 22 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.